U.S. markets closed

Citius Pharmaceuticals, Inc. (CTXR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0600-0.1600 (-7.21%)
At close: 4:00PM EST

2.0200 -0.04 (-1.94%)
After hours: 7:59PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.2200
Open2.1000
Bid2.0000 x 21500
Ask2.0400 x 2900
Day's Range1.9900 - 2.2200
52 Week Range0.4150 - 2.9000
Volume18,954,691
Avg. Volume10,457,425
Market Cap259.117M
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-0.4670
Earnings DateDec 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
    PR Newswire

    Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has closed its previously announced sale of an aggregate of 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock, at a purchase price of $1.505 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules.

  • CTXR Stock: 9 Things to Know About the Biotech Citius Pharma as Shares Surge
    InvestorPlace

    CTXR Stock: 9 Things to Know About the Biotech Citius Pharma as Shares Surge

    Citius Pharmaceuticals (NASDAQ:CTXR) stock is on the rise Friday despite a lack of news about the company today. Source: Shutterstock The jump in price for CTXR stock comes alongside an increase in trading. As of this writing, more than 84 million shares of the stock have changed hands. For some context, the company’s daily average trading volume is roughly 4 million shares. So why exactly is CTXR stock up today? It’s worth noting that the company announced a direct offering on Wednesday for 50,830,566 shares and warrants for another 25,415,283 shares. That direct offering is expected to close today.InvestorPlace - Stock Market News, Stock Advice & Trading Tips 7 Overvalued Stocks Investors Just Don’t Get Tired Of Keeping these things in mind, here’s what investors need to know about the company as shares of CTXR stock surge. Citius Pharma is a late-stage specialty pharmaceutical company. This has it working on the development and commercialization of critical care products. Its focus includes anti-infectives and cancer care. The company is currently developing three proprietary candidates. They are Mino-Lok, CITI-002, and CITI-101. Mino-Lok is the furthest along of these with a Phase 3 clinical trial currently underway. Citius Pharma is led by president and CEO Myron Holubiak alongside chairman Leonard Mazur. It was founded in 2010 and joined the public market via an initial public offering (IPO) in September 2014. The company operates out of its headquarters in Cranford, N.J. CTXR stock was up 23.8% as of Friday morning and is up 84.6% since the start of the year. On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next Potential Winner It doesn’t matter if you have $500 in savings or $5 million. Do this now. #1 Play to Profit from Biden's Presidency The post CTXR Stock: 9 Things to Know About the Biotech Citius Pharma as Shares Surge appeared first on InvestorPlace.

  • Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
    PR Newswire

    Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the purchase of an aggregate of 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock, at a purchase price of $1.505 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to take place on or about February 19, 2021, subject to the satisfaction of customary closing conditions.